Sophie He/LinkedIn
Aug 12, 2026, 06:01
Sophie He: Exploring Manufacturing Scalability and Cell Separation
Sophie He, Vice President Cell Therapy, Head of M&A and Partnering at Bracco shared a post on LinkedIn:
“In my latest interview with Technology Networks, I explored a critical but often overlooked bottleneck: manufacturing scalability and cell separation.
Cell and gene therapies have opened the potential to curing once – incurable conditions like sickle cell disease.
But approval is only half the story – the real question is, how many patients actually get treated?
Thank you to Izzy Hirst and Anna-Marie MacDonald at Technology Networks for the great conversation.
Full interview here.”
Stay updated with Hemostasis Today.
-
Sep 29, 2026, 16:21Yitshak Kreiss: From Treating Patients to Defining the Standard of Knowledge
-
Sep 29, 2026, 16:18Edward Lee Carter: Why Periprocedural DOAC Guidance Needs a Common Output Standard
-
Sep 29, 2026, 16:07Yasmine Laraba: Deep Vein Thrombosis Causes, Signs and Management
-
Sep 29, 2026, 16:01Stephen Cornelissen: How Joining the Stem Cell Registry Can Save Patients with Blood Cancers
-
Sep 29, 2026, 15:45Alan Nurden: Could Mast Cell aIIb Integrin Play a Key Role in Septic Thrombus Stability?
-
Sep 29, 2026, 15:43Priyadarshani Sharma: Advocacy and Patient Rights Transform Indian Haemoglobinopathies Care
-
Sep 29, 2026, 15:21Kanchan K Banerjee: Rusfertide Earns NCCN Category 1 Recommendation for Polycythemia Vera
-
Sep 29, 2026, 15:06Faizan KhanÖ‰ The Worldwide Burden of Venous Thromboembolism
-
Sep 29, 2026, 14:59Global Von Willebrand Disease Diversity Webinar Now Available on EHC YouTube – EHC